Literature DB >> 20063428

The spectrum of movement disorders in Glut-1 deficiency.

Roser Pons1, Abbie Collins, Michael Rotstein, Kristin Engelstad, Darryl C De Vivo.   

Abstract

To assess the spectrum of movement disorders, we reviewed video recordings and charts of 57 patients with Glut-1 deficiency. Eighty-nine percent of patients with Glut-1 deficiency syndrome had a disturbance of gait. The most frequent gait abnormalities were ataxic-spastic and ataxic. Action limb dystonia was observed in 86% of cases and mild chorea in 75%. Cerebellar action tremor was seen in 70% of patients, myoclonus in 16%, and dyspraxia in 21%. Nonepileptic paroxysmal events occurred in 28% of patients, and included episodes of ataxia, weakness, Parkinsonism and nonkinesogenic dyskinesias. The 40 patients (70%) who were on the ketogenic diet had less severe gait disturbances but more dystonia, chorea, tremor, myoclonus, dyspraxia, and paroxysmal events compared with the 17 patients on a conventional diet. Poor dietary compliance and low ketonuria appear to trigger the paroxysmal events in some patients. Gait disturbances and movement disorders are frequent in patients with Glut-1 deficiency and are signs of chronic and intermittent pyramidal, cerebellar and extrapyramidal circuit dysfunction. These clinical symptoms reflect chronic nutrient deficiency during brain development and may be mitigated by chronic ketosis. (c) 2009 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20063428     DOI: 10.1002/mds.22808

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  42 in total

1.  Excellent response to acetazolamide in a case of paroxysmal dyskinesias due to GLUT1-deficiency.

Authors:  Mathieu Anheim; Elisabeth Maillart; Sandrine Vuillaumier-Barrot; Constance Flamand-Rouvière; Fanny Pineau; Claire Ewenczyk; Florence Riant; Emmanuelle Apartis; Emmanuel Roze
Journal:  J Neurol       Date:  2010-09-10       Impact factor: 4.849

2.  Paroxysmal ocular movements - an early sign in Glut1 deficiency Syndrome.

Authors:  Sofia Reis; Joana Matias; Raquel Machado; José Paulo Monteiro
Journal:  Metab Brain Dis       Date:  2018-05-05       Impact factor: 3.584

3.  A Case of Progressive Chorea Resulting From GLUT1 Deficiency.

Authors:  Ichraf Kraoua; Hanene Benrhouma; Sandrine Vuillaumier-Barrot; Hedia Klaa; Ilhem Ben Youssef-Turki
Journal:  Mov Disord Clin Pract       Date:  2015-08-18

4.  Pediatric movement disorders: Five new things.

Authors:  Joanna S Blackburn; Jonathan W Mink; Erika F Augustine
Journal:  Neurol Clin Pract       Date:  2012-12

5.  Dietary Treatments and New Therapeutic Perspective in GLUT1 Deficiency Syndrome.

Authors:  Pierangelo Veggiotti; Valentina De Giorgis
Journal:  Curr Treat Options Neurol       Date:  2014-05       Impact factor: 3.598

6.  A Cause of Permanent Ketosis: GLUT-1 Deficiency.

Authors:  Alexis Chenouard; Sandrine Vuillaumier-Barrot; Nathalie Seta; Alice Kuster
Journal:  JIMD Rep       Date:  2014-09-26

7.  Paroxysmal exercise-induced dystonia due to GLUT1 mutation can be responsive to levodopa: a case report.

Authors:  Francesca Baschieri; Amit Batla; Roberto Erro; Christos Ganos; Carla Cordivari; Kailash P Bhatia
Journal:  J Neurol       Date:  2014-02-02       Impact factor: 4.849

8.  Glut1 deficiency: inheritance pattern determined by haploinsufficiency.

Authors:  Michael Rotstein; Kristin Engelstad; Hong Yang; Dong Wang; Brynn Levy; Wendy K Chung; Darryl C De Vivo
Journal:  Ann Neurol       Date:  2010-12       Impact factor: 10.422

9.  Severe familial paroxysmal exercise-induced dyskinesia.

Authors:  Pawel Tacik; Sebastian Loens; Christoph Schrader; Sabine Gayde-Stephan; Saskia Biskup; Dirk Dressler
Journal:  J Neurol       Date:  2014-08-07       Impact factor: 4.849

Review 10.  Phenotypic spectrum of glucose transporter type 1 deficiency syndrome (Glut1 DS).

Authors:  Toni S Pearson; Cigdem Akman; Veronica J Hinton; Kristin Engelstad; Darryl C De Vivo
Journal:  Curr Neurol Neurosci Rep       Date:  2013-04       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.